Clearbridge Investments LLC decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,180 shares of the biopharmaceutical company’s stock after selling 1,800 shares during the quarter. Clearbridge Investments LLC’s holdings in Bristol-Myers Squibb were worth $6,734,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the business. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,560,524,000. Primecap Management Co. CA grew its position in shares of Bristol-Myers Squibb by 14.6% during the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company’s stock worth $1,207,549,000 after buying an additional 2,998,228 shares during the period. Dimensional Fund Advisors LP boosted its stake in Bristol-Myers Squibb by 7.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 16,959,807 shares of the biopharmaceutical company’s stock worth $870,198,000 after acquiring an additional 1,246,066 shares during the last quarter. Pzena Investment Management LLC boosted its stake in Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company’s stock worth $666,699,000 after acquiring an additional 6,701,097 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Bristol-Myers Squibb by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 11,361,717 shares of the biopharmaceutical company’s stock valued at $582,970,000 after buying an additional 134,815 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol-Myers Squibb Trading Up 1.4 %
Shares of Bristol-Myers Squibb stock traded up $0.63 during midday trading on Thursday, reaching $45.29. 1,121,882 shares of the company’s stock traded hands, compared to its average volume of 15,625,283. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The company has a market cap of $91.81 billion, a PE ratio of -14.41, a price-to-earnings-growth ratio of 15.94 and a beta of 0.44. The stock has a 50 day moving average of $41.60 and a 200-day moving average of $46.84. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.89.
Bristol-Myers Squibb Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.30%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.
Analyst Upgrades and Downgrades
BMY has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Barclays reduced their target price on shares of Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a report on Monday. Finally, BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $57.73.
Check Out Our Latest Research Report on BMY
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- How to Calculate Return on Investment (ROI)
- Beauty Retailer Stock Brings Early Christmas for Value Investors
- Roth IRA Calculator: Calculate Your Potential Returns
- Ford Stock EPS Disappoints, Shares Plummet After-Hours
- Stock Average Calculator
- How Much Should You Be Investing? Try Our Calculators
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.